source
- Fulcrum exploring a potential sale after FDA sidelined its sickle cell drugFulcrum’s setback is the latest in a series of stumbles for the developers of sickle cell medicines, among them Pfizer, Novartis and Intellia Therapeutics.BioPharma Dive · 1mo ago↗ source
- FDA Issues Draft Guidance to Help Accelerate Cell and Gene Therapies for PatientsThe U.S. Food and Drug Administration (FDA) today issued draft guidance to help developers bring promising gene therapies to patients more efficiently by making greater use of existing scientific a…fda press · 1mo ago↗ source
- AbiVax falls as safety worries cloud ‘landmark’ immune drug resultsA handful of cancer cases reported among treatment recipients overshadowed efficacy results analysts described as “best-in-disease” and sent shares down more than 30%.